<DOC>
	<DOCNO>NCT01090453</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity GSK Biologicals ' GSK2202083 vaccine co-administered Prevenar 13® 2 , 4 12 month age Rotarix™ 2 4 month age .</brief_summary>
	<brief_title>Study GlaxoSmithKline Biologicals ' GSK2202083A Vaccine Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) comply requirement protocol . A male female infant , include , 8 12 week time first vaccination . Born gestation period 36 42 week inclusive . Written inform consent obtain parent ( ) , Legally Acceptable Representative ( ) subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Child care . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration vaccine foreseen study protocol within 30 day prior randomisation , plan administration randomisation end study exception inactivate influenza vaccine . The administration diphtheria , tetanus , pertussis , hepatitis B , poliomyelitis , Haemophilus influenzae type b , pneumococcal , rotavirus and/or MenC vaccine allow time study period vaccine allow period one day study Visit 3 31 day study Visit 4 . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous diphtheria , tetanus , pertussis , hepatitis B , poliomyelitis , Hib , pneumococcal , rotavirus and/or MenC vaccination disease , include Hepatitis B virus vaccination birth . History seizures progressive neurological disease . Subjects history intussusception uncorrected congenital malformation gastrointestinal tract would predispose intussusception . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . The following condition temporary selflimiting , subject may vaccinate condition resolve exclusion criterion meet : Current febrile illness moderate severe illness within 24 hour study vaccine administration . Current gastrointestinal infection .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>